As demand for CAR T therapies strain traditional manufacturing, Autolus Therapeutics has tapped Cellares to evaluate whether that company’s automated Cell Shuttle platform can support expanded ...

The latest OXB agreement will help advance the company’s CAR-T therapies and provide a “reliable, scalable manufacturing ...

Cellares, which last year became the first company to receive the FDA's new advanced manufacturing technology designation, ...

Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...

As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...

RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes engineered cancer-fighting immune cells behave more like stem cells, improving ...

CAR T-cell therapy, considered one of the most promising breakthroughs in cancer treatment, works by harnessing the patient’s own immune system ...

Cellares and City of Hope announced a collaboration Jan. 8 to evaluate automated manufacturing for an investigational CAR T cell therapy. The effort will target glioblastoma multiforme, a fast-growing ...

Collaboration focuses on City of Hope’s IL13RA2-EGFR targeting CAR T cell program addressing a type of fast-growing, aggressive brain cancer called glioblastoma multiforme. The collaboration addresses ...